Every year it is estimated that there are 12,000 spinal cord injuries in the US alone (http://www.ninds.nih.gov/disorders/sci/detail_sci.htm). These are life changing injuries for which there is currently no cure. Long term care of patients suffering from spinal cord injury is not only extremely expensive, it is emotionally and physically challenging in ways few could ever understand. Cord blood could provide hope to those who so desperately need it.
Special LIVE EVENT during 2016 AABB Conference in Orlando, Florida
SHARE THE SCIENCE
Wise Young, MD, Phd
“Cord Blood Therapies as Potential Treatments for People with Chronic Spinal Cord Injury”
Orange County Convention Center, room W224GH Orlando, FL
Monday, October 24, 2016
7:00 – 8:15 a.m. eastern time
NOTE: This was a special LIVE event held during the
2016 AABB Conference in Orlando, Florida. This presentation was not recorded.
Dr. Wise Young, M.D., Ph.D., Distinguished Professor, founding director of the W.M. Keck Center for Collaborative Neuroscience and a distinguished professor, is recognized as one of the world’s outstanding neuroscientists.
His accolades are many yet what makes him a leading researcher in the cord blood industry is his commitment to bringing treatments to people with spinal cord Injuries. He built and trained a 25 center clinical trial network in China, Taiwan, and Hong Kong, where human clinical trials using umbilical cord blood mononuclear cells and lithium are underway. In the initial results from the phase II trial in Kunming, China, 75% of the participants (15 out of 20) recovered walking with a rolling walker. He is establishing clinical trial networks in the United States, Norway, and India. Phase IIB trials started in 2015, and phase III trials are getting underway this year.
We are truly honored to have Dr. Young join us for this special edition of “Share the Science” during the 2016 AABB Conference.
Attendees of this live “Share the Science” presentation will hear Dr. Young give details on his groundbreaking research “Cord Blood Therapies as Potential Treatments for People with Chronic Spinal Cord Injury.” Dr. Young will begin with a discussion about the rationale for his work. . .
“In the past decade, hundreds of laboratories have reported that UCB cells, particularly UCB mononuclear cells (UCBMNC), have beneficial effects on a variety of conditions, including cerebral palsy, stroke, and spinal cord injury. Several groups have done clinical trials transplanting UCBMNC into the brain and spinal cords of patients, suggesting that the therapies are safe and possibly beneficial. We sought to test the safety and efficacy of UCBMNC transplanted into people with chronic complete spinal cord injury. In addition, because animal studies suggest that lithium stimulates UCBMNC to grow and to produce growth factors that stimulate regeneration, we wanted to assess the effects of a 6-week course of oral lithium carbonate given to patients after transplant of UCBMNC.”
Dr. Young will also discuss in detail:
- Why exercise is necessary but not sufficient for recovery
- How people can recover even after chronic complete spinal cord injury
- Skepticism of claims that intrathecal administration of UCBMNC will be effective for chronic spinal cord injury, particularly without intensive rehabilitation
Attendees of this presentation will learn about various clinical applications using UCBMNC to treat spinal cord injury, results of these trials by Dr. Young and how people can recover from chronic spinal injury.
* * *
We wish to thank Dr. Young for participating in “Share the Science” and sharing his valuable insight on using cord blood to potentially treat spinal cord injuries.
We also wish to thank our generous sponsors, Mediware Inc., who continue to support cord blood education through our “Share the Science” series.